Updates are available Correction dated 2022-06-29
Click to view Correction: https://doi.org/10.1186/s13059-022-02704-z
-
Authors
Barrett, James E.
Herzog, Chiara
Kim, Yoo-Na
Bartlett, Thomas E.
Jones, Allison
Evans, Iona
Cibula, David
Zikan, Michal
Bjørge, Line
Harbeck, Nadia
Colombo, Nicoletta
Howell, Sacha J.
Rådestad, Angelique Flöter
Gemzell-Danielsson, Kristina
Widschwendter, Martin http://orcid.org/0000-0002-7778-8380
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (874662)
European Research Council (742432)
The Eve Appeal
Vetenskapsrådet (2017-00932, 2012-02961)
Manchester Biomedical Research Centre (IS-BRC-1215-20007)
- License Information
-
More Information
Article History
Received: 27 February 2021
Accepted: 5 January 2022
First Online: 22 February 2022
Change Date: 29 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13059-022-02704-z
Declarations
:
: The FORECEE (4C) Program has ethical approval from the UK Health Research Authority (REC 14/LO/1633) and other contributing centers. For assessing the breast tissue samples, we obtained ethical approval from the regional ethical review board at the Karolinska Institutet (permit 2009/144-31/4) and from the NRES Committee East of England (reference number 15/EE/0192) and from the regional ethical review board at Greater Manchester – South (Research Ethics Committee REC number 15/NW/0478).
: UCL Business Ltd (UCL’s commercialization company) has filed a patent on some aspects described in the paper—MW and JEB are named as inventors on this patent.
